Navigation Links
Novexel's NXL104/ceftazidime Combination Commences Second Phase II Clinical Trial in Hospital Patients With Complicated Intra-Abdominal Infections (cIAIs)
Date:3/3/2009

About NXL104

NXL104 is a novel injectable non beta lactam, beta-lactamase inhibitor, which is being developed to address the increasing problem of microbial resistance to beta lactam antibiotics (penicillins, cephalosporins, carbopenems) mediated by beta-lactamase enzymes.

NXL104 is a significant advance, as it is able to inhibit a broader range of beta-lactamases than currently marketed inhibitors. Its spectrum includes class A (including ESBL and KPC) and class C enzymes. NXL104 in combination with ceftazidime will be targeting infections caused by Gram negative bacteria, including Enterobacteriaceae and Pseudomonas.

About Novexel

Novexel is a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance. The ever increasing resistance to marketed antibiotics has led to a clear need for novel drugs that are active against multi-drug resistant bacteria. Novexel's products are targeting the global hospital antibiotic market, which was worth an estimated $15bn in 2007 according to information derived from the IMS Midas(R) database.

Novexel currently has two novel antibacterials in Phase II clinical development. These are the injectable beta-lactamase inhibitor, NXL104, which is being developed in combination with the cephalosporin antibiotic ceftazidime for serious Gram negative infections, and the oral streptogramin antibiotic, NXL103, for the treatment of Gram positive infections, with a focus on treatment in the hospital setting and intravenous (IV) to oral switch. Novexel has three further programmes in preclinical development, NXL105, a novel anti-Pseudomonal antibiotic, NXL201, a novel echinocandin antifungal agent, and NXL104 in combination with ceftaroline. This latter product is being developed by our partner, Forest Laboratories, solely for North
'/>"/>

SOURCE Novexel
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Novexels NXL104/ceftazidime Combination Commences Phase II Clinical Trial in Hospital Patients With Complicated Urinary Tract Infections
2. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
3. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
4. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
5. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
6. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
7. Vion Pharmaceuticals Announces Initiation of a Phase I/II Trial of Cloretazine(R) (VNP40101M) in Combination with Temodar(R) in Adult Brain Tumors
8. New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy
9. New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients With Complicated Skin Infections, Including MRSA
10. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
11. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... Calif. , June 30, 2015  Ardelyx, Inc. ... on cardio-renal, gastrointestinal and metabolic diseases, today announced that ... July 14, 2015, from 8:00 a.m.- 1:00 pm EDT ... The Ardelyx senior management team will present ... lead compound, tenapanor, which has completed Phase 2b clinical ...
(Date:6/30/2015)... 30, 2015  July 4 th is this weekend, ... the spirit and people behind it. To help honor our ... USA Medical Card, a leading provider ... programs that empower independence for our disabled military veterans, police, ... people afford their prescriptions. "Due to ...
(Date:6/30/2015)... WAYNE, Pa. , June 30, 2015 ... ("Egalet"), a fully integrated specialty pharmaceutical company ... pain treatments, today announced top-line results from ... study of Egalet-002, an abuse-deterrent, extended-release, oral ... for the management of pain severe enough ...
Breaking Medicine Technology:Ardelyx to Host Inaugural R&D Investor Day in New York City on July 14, 2015 2Hope For Heroes and USA Medical Card Make a Difference for Our Nation's Heroes 2Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 2Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 3Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 4Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 5
... Misonix, Inc. (Nasdaq: MSON ), a developer ... which worldwide is used for acute health conditions, today ... year ending June 30, 2010.  Michael A. McManus, Jr., ... VP and Chief Financial Officer, will host a conference ...
... YORK, Sept. 28 Reportlinker.com announces that a new ... Global In Vitro Diagnostics (IVD) Market Report: ... The global IVD market has been experiencing ... has been growing awareness about health and prevention of ...
Cached Medicine Technology:Misonix Reports Fourth Quarter and Fiscal Year 2010 Financial Results 2Misonix Reports Fourth Quarter and Fiscal Year 2010 Financial Results 3Misonix Reports Fourth Quarter and Fiscal Year 2010 Financial Results 4Misonix Reports Fourth Quarter and Fiscal Year 2010 Financial Results 5Misonix Reports Fourth Quarter and Fiscal Year 2010 Financial Results 6Misonix Reports Fourth Quarter and Fiscal Year 2010 Financial Results 7Misonix Reports Fourth Quarter and Fiscal Year 2010 Financial Results 8Misonix Reports Fourth Quarter and Fiscal Year 2010 Financial Results 9Reportlinker Adds Global In Vitro Diagnostics (IVD) Market Report: 2010 Edition 2Reportlinker Adds Global In Vitro Diagnostics (IVD) Market Report: 2010 Edition 3Reportlinker Adds Global In Vitro Diagnostics (IVD) Market Report: 2010 Edition 4Reportlinker Adds Global In Vitro Diagnostics (IVD) Market Report: 2010 Edition 5
(Date:6/30/2015)... ... June 30, 2015 , ... Ticket Down is a reliable source for last minute ... band has been packing stadiums across North America in conjunction with their 2015 “Zip Code ... the energy of a band in their twenties. Some of the most beloved songs ...
(Date:6/30/2015)... ... June 30, 2015 , ... Earlier ... Introduction to Hyperbaric Medicine Course. Clinicians from WCA partnering hospitals across the country, ... , Wound care and hyperbaric medicine education and training is something that ...
(Date:6/30/2015)... ... June 30, 2015 , ... The LIV Fertility ... fertility preservation and deciding the right age to pursue egg freezing. Statistics show that ... age of 35 — a 150 percent increase since the 1970s. , Sadly, for ...
(Date:6/30/2015)... ... June 30, 2015 , ... University Post-Acute ... video focuses on the rehab center’s patients and their experiences at the facility. ... quality of services available. Each patient attests to the high rating, which is ...
(Date:6/30/2015)... ... June 30, 2015 , ... Lakeview ... more than doubled the size of its medical staff to further enhance its ... which includes physicians, nurse practitioners and physician assistants -- now totals 17, compared ...
Breaking Medicine News(10 mins):Health News:The Rolling Stones Tickets in Raleigh at Carter Finley Stadium: Ticket Down Offers Last Minute Tickets for the Rolling Stones and Avett Brothers in Raleigh 2Health News:Wound Care Advantage Hosts Its First UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 2Health News:Wound Care Advantage Hosts Its First UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 3Health News:LIV Fertility Center Educating Women on the Critical Timing of Egg Freezing 2Health News:LIV Fertility Center Educating Women on the Critical Timing of Egg Freezing 3Health News:LIV Fertility Center Educating Women on the Critical Timing of Egg Freezing 4Health News:LIV Fertility Center Educating Women on the Critical Timing of Egg Freezing 5Health News:Patients of University Post-Acute Rehab Support Five-Star Rating in New Video 2Health News:Lakeview Health, a Nationally Recognized Drug Rehabilitation Center in Florida, Doubles Size of Medical Staff 2
... By Ellin Holohan HealthDay Reporter , WEDNESDAY, ... think they weigh less than they do, and many mothers ... research finds. The study of women and children conducted ... that faulty body image was far more prevalent among the ...
... Steven Reinberg HealthDay Reporter , WEDNESDAY, March 23 ... old on Wednesday, and the health-care reform package -- the ... remains as controversial as the day it was signed into ... States," said Greg Scandlen, director of Consumers for Health Care ...
... HOUSTON - Noted hematologist Edward J. Benz Jr., M.D., is ... for Promotion of Women in Cancer Medicine and Cancer Science ... Benz, president and chief executive officer of Dana-Farber Cancer ... MD Anderson. The first male recipient of the ...
... Today, the European Congress on Osteoporosis and Osteoarthritis ... international participants. The Congress is the major annual ... clinicians, specialists and bone experts from around the ... Palacio de Congresos. A joint event of ...
... helps you say yes to NO , ,Disorders of ... world, and can lead to heart attacks, strokes and even ... and angioplasty, themselves induce vascular injury, after which the cells ... limits blood flow. Nitric oxide (NO) is an important molecule ...
... -- People of normal weight eat more when they sleep ... discovered that sleep-deprived adults ate almost 300 calories more a ... the extra calories mostly came from saturated fat, which can ... the most impacted by lack of sleep. They ate an ...
Cached Medicine News:Health News:Many Obese Moms and Kids Underestimate Their Weight 2Health News:Many Obese Moms and Kids Underestimate Their Weight 3Health News:As Health Care Reform Turns 1, Backers and Detractors Dig In 2Health News:As Health Care Reform Turns 1, Backers and Detractors Dig In 3Health News:As Health Care Reform Turns 1, Backers and Detractors Dig In 4Health News:Benz wins Kripke Award for promoting women in science, medical careers 2Health News:JCI online early table of contents: March 23, 2011 2Health News:JCI online early table of contents: March 23, 2011 3Health News:JCI online early table of contents: March 23, 2011 4Health News:JCI online early table of contents: March 23, 2011 5Health News:JCI online early table of contents: March 23, 2011 6Health News:JCI online early table of contents: March 23, 2011 7Health News:JCI online early table of contents: March 23, 2011 8Health News:JCI online early table of contents: March 23, 2011 9Health News:JCI online early table of contents: March 23, 2011 10
... Stainless steel spiral reinforced. X-ray opaque . Low ... Flange: The flange can be adjusted along the ... cervical soft tissue. The lock ring is turned ... the shaft. Maximum Patient Comfort: The tube is ...
... Per-fit™ tubes are a dual ... of the disposable inner cannula ... provided in the procedural tray. ... tubes are available separately. Per-fit™ ...
Manufactured form the same soft siliconized PVC as all Portex® Blue Line® tracheostomy tubes....
Thermosensitivity of material allows tube to conform to patients anatomy for maximum patient comfort....
Medicine Products: